Form 4: Arcus Biosciences COO Jennifer Jarrett Sells Shares

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold 11,551 shares of common stock at an average price of $17.55 on March 27, 2024, according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 27, 2024, Jennifer Jarrett, the Chief Operating Officer of Arcus Biosciences, sold 11,551 shares of the company's common stock.
• The sale was executed at a weighted average price of $17.55 per share.
• The transactions occurred within a price range of $17.53 to $17.62.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 22, 2023.
• Following the transaction, Jarrett directly owns 215,253 shares of Arcus Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-existing trading plan. There is no indication of positive or negative implications for the company's future performance.

Industry Context

Sales by company executives are a normal part of corporate activity. Investors often look to the reasons behind the sale, such as diversification or personal financial planning. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on immediate insider knowledge.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates